We propose to continue the extraordinarily successful Global Alliance in Pharmacogenomics- Japan (GAP-J) as a network resource for the Pharmacogenomics Research Network (PGRN). GAP-J (see Figure XII.1) is an existing alliance (see http://vwvw.nigms.nih.gov/lnitiatives/PGRN/GAP/) between the PGRN and the Center for Genomic Medicine (CGM) of the Riken, Yokohama Institute in Japan (see www.src.riken.ip/english/for description of CGM). This international alliance brings together scientists in multiple research disciplines to conduct research in pharmacogenomics. In particular, the research focuses on genomewide association studies to identify genetic predictors of therapeutic and adverse reactions to medicines. GAP-J was started after initial discussions between Dr. Yusuke Nakamura, Director of the CGM and Drs. Mark Ratain and Kathy Giacomini, Principal Investigators in the PGRN. The discussions centered on the need to expedite discoveries in pharmacogenomics so that personalized medicines could be realized. A partnership between the PGRN, which would contribute rich sets of well-phenotyped samples and the CGM, which would contribute powerful high throughput genomewide methods, was discussed. Formal launching of GAP-J occurred in the Spring of 2008 with a letter of intent signed by Dr. Yusuke Nakamura, Director of the Center for Genome Medicine, Riken;Dr. Scott Weiss, Chair, Pharmacogenefics Research Network;and NIH Institute Directors, Drs. Jeremy Berg (National Institute of General Medical Sciences), John Niederhuber (National Cancer Institute) and Elizabeth Nabel (National Heart, Lung and Blood Institute). Currently fourteen research collaborations focused on genomewide association analysis of many drug response phenotypes are underway in GAP-J (see Table XII.1).

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19GM061390-15
Application #
8689086
Study Section
Special Emphasis Panel (ZRG1-GGG-M)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
15
Fiscal Year
2014
Total Cost
$722,061
Indirect Cost
$165,254
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Chen, Ligong; Shu, Yan; Liang, Xiaomin et al. (2014) OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin. Proc Natl Acad Sci U S A 111:9983-8
Smith, Robin P; Eckalbar, Walter L; Morrissey, Kari M et al. (2014) Genome-wide discovery of drug-dependent human liver regulatory elements. PLoS Genet 10:e1004648
VanderMeer, Julia E; Lozano, Reymundo; Sun, Miao et al. (2014) A novel ZRS mutation leads to preaxial polydactyly type 2 in a heterozygous form and Werner mesomelic syndrome in a homozygous form. Hum Mutat 35:945-8
Clancy, J P; Johnson, S G; Yee, S W et al. (2014) Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for ivacaftor therapy in the context of CFTR genotype. Clin Pharmacol Ther 95:592-7
Chhibber, A; Mefford, J; Stahl, E A et al. (2014) Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance). Pharmacogenomics J 14:336-42
Erwin, Genevieve D; Oksenberg, Nir; Truty, Rebecca M et al. (2014) Integrating diverse datasets improves developmental enhancer prediction. PLoS Comput Biol 10:e1003677
VanderMeer, Julia E; Smith, Robin P; Jones, Stacy L et al. (2014) Genome-wide identification of signaling center enhancers in the developing limb. Development 141:4194-8
Larregieu, Caroline A; Benet, Leslie Z (2014) Distinguishing between the permeability relationships with absorption and metabolism to improve BCS and BDDCS predictions in early drug discovery. Mol Pharm 11:1335-44
Kim, Mee J; Oksenberg, Nir; Hoffmann, Thomas J et al. (2014) Functional characterization of SIM1-associated enhancers. Hum Mol Genet 23:1700-8
Martin, M A; Hoffman, J M; Freimuth, R R et al. (2014) Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update. Clin Pharmacol Ther 95:499-500

Showing the most recent 10 out of 44 publications